239 related articles for article (PubMed ID: 17671173)
1. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.
Treszezamsky AD; Kachnic LA; Feng Z; Zhang J; Tokadjian C; Powell SN
Cancer Res; 2007 Aug; 67(15):7078-81. PubMed ID: 17671173
[TBL] [Abstract][Full Text] [Related]
2. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.
Kachnic LA; Li L; Fournier L; Ferraiolo N; Dahm-Daphi J; Borgmann K; Willers H
Cancer Lett; 2011 Jun; 305(1):86-93. PubMed ID: 21414716
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-related secondary leukemias: A role for DNA repair by error-prone non-homologous end joining in topoisomerase II - Induced chromosomal rearrangements.
Kantidze OL; Razin SV
Gene; 2007 Apr; 391(1-2):76-9. PubMed ID: 17234368
[TBL] [Abstract][Full Text] [Related]
4. DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II.
Caldecott K; Banks G; Jeggo P
Cancer Res; 1990 Sep; 50(18):5778-83. PubMed ID: 2168280
[TBL] [Abstract][Full Text] [Related]
5. Dependence of etoposide-induced cytotoxicity and topoisomerase II-mediated DNA strand breakage on the intracellular ionic environment.
Lawrence TS; Canman CE; Maybaum J; Davis MA
Cancer Res; 1989 Sep; 49(17):4775-9. PubMed ID: 2547516
[TBL] [Abstract][Full Text] [Related]
6. The role of nonhomologous DNA end joining, conservative homologous recombination, and single-strand annealing in the cell cycle-dependent repair of DNA double-strand breaks induced by H(2)O(2) in mammalian cells.
Frankenberg-Schwager M; Becker M; Garg I; Pralle E; Wolf H; Frankenberg D
Radiat Res; 2008 Dec; 170(6):784-93. PubMed ID: 19138034
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
8. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
Fedier A; Steiner RA; Schwarz VA; Lenherr L; Haller U; Fink D
Int J Oncol; 2003 May; 22(5):1169-73. PubMed ID: 12684687
[TBL] [Abstract][Full Text] [Related]
9. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
10. DNA-PKcs-dependent NHEJ pathway supports the progression of topoisomerase II poison-induced chromosome aberrant cells.
Elguero ME; de Campos-Nebel M; González-Cid M
Environ Mol Mutagen; 2012 Oct; 53(8):608-18. PubMed ID: 22987276
[TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest.
Yun J; Zhong Q; Kwak JY; Lee WH
Oncogene; 2005 Jun; 24(25):4009-16. PubMed ID: 15782115
[TBL] [Abstract][Full Text] [Related]
12. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
13. Cell fusion studies to examine the mechanism for etoposide resistance in Chinese hamster V79 spheroids.
Luo C; Johnston PJ; MacPhail SH; Banáth JP; Oloumi A; Olive PL
Exp Cell Res; 1998 Sep; 243(2):282-9. PubMed ID: 9743588
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
15. [Cytotoxic mechanism and antineoplastic action of etoposide].
Dołega A
Postepy Hig Med Dosw; 1998; 52(1):67-87. PubMed ID: 9608232
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells.
Vernole P; Muzi A; Volpi A; Dorio AS; Terrinoni A; Shah GM; Graziani G
Mutat Res; 2009 May; 664(1-2):39-47. PubMed ID: 19428379
[TBL] [Abstract][Full Text] [Related]
17. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2.
Godthelp BC; van Buul PP; Jaspers NG; Elghalbzouri-Maghrani E; van Duijn-Goedhart A; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Oct; 601(1-2):191-201. PubMed ID: 16920162
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis of unstimulated human lymphocytes and DNA strand breaks induced by the topoisomerase II inhibitor etoposide (VP-16).
Tronov VA; Konoplyannikov MA; Nikolskaya TA; Konstantinov EM
Biochemistry (Mosc); 1999 Mar; 64(3):345-52. PubMed ID: 10205305
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication.
Fridlich R; Annamalai D; Roy R; Bernheim G; Powell SN
DNA Repair (Amst); 2015 Jun; 30():11-20. PubMed ID: 25836596
[TBL] [Abstract][Full Text] [Related]
20. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]